Datamonitor's October
edition of the Cancer Review brings you the latest news, expert analysis
and research in the cancer industry.
It covers all the major current business
issues and events, including R&D, licensing deals, alliances and joint
ventures, and regulatory decisions.
Scope
-
Strategic insight into the future shape
of cancer companies and markets
-
The most significant cancer industry
news compiled into one monthly update
-
Expert analysis into the implications
of the month's important cancer industry events
-
Insight into the future shape of the
market for players at all levels
-
All the month's cancer stories in
headline and summary form
Report Highlights
Out of the dozens of topics covered in this
month's review, the most important include:
* Novartis's Gleevec was granted a priority
review by the FDA for possible use as a first-line treatment for newly
diagnosed patients with Philadelphia-chromosome positive chronic myeloid
leukemia in the chronic phase, the earliest stage of the disease.
* A US District Court jury found
unanimously in favor of Genentech following the claims of Chiron's that
Genentech had infringed a patent with their metastatic breast cancer drug,
Herceptin.
Reasons to Purchase
-
Not only keeps you updated about
industry events - it also gives you opinion and insight
-
Draws upon Datamonitor analysts'
extensive experience to bring you our perspective on the impact of the
latest events
-
Provides you with your own news archive
to track company and industry progress, giving you an extensive
reference to relevant events and issues
R&D UPDATE: BREAST CANCER
The most significant news
in breast cancer R&D, compiled into one monthly update.
R&D UPDATE: LUNG CANCER
The most significant news
in lung cancer R&D, compiled into one monthly update.
R&D UPDATE: PROSTATE CANCER
The most significant news
in prostate cancer R&D, compiled into one monthly update.
R&D UPDATE: COLORECTAL CANCER
The most significant news
in colorectal cancer R&D, compiled into one monthly update.
R&D UPDATE: OTHER CANCERS
The most significant news
in other cancers, compiled into one monthly update including:
-
Lymphoma and leukemia
-
Brain cancer
-
Ovarian cancer
-
Liver cancers
LATEST COMMENT
Expert analysis of the
implications of the month's important industry events
-
Novartis: multiple roles for Gleevec
-
AstraZeneca: a nail in the coffin of
EGFr inhibitor hopes
-
Novuspharma: lending a hand to
Micromet
-
Chiron/Genentech: battling on despite
Herceptin ruling
MARKET SNAPSHOTS
Insight into the future
shape of the market for players at all levels
-
Tumors: breast most common in 2001
-
Malignant melanoma: incidence to hit
77,000 in 2010
NEWS HEADLINES - BREAST CANCER
All the month's breast
cancer news stories in headline and summary form
NEWS HEADLINES - LUNG CANCER
All the month's lung cancer
news stories in headline and summary form
NEWS HEADLINES - PROSTATE CANCER
All the month's prostate
cancer news stories in headline and summary form
NEWS HEADLINES - COLORECTAL CANCER
All the month's colorectal
cancer news stories in headline and summary form
NEWS HEADLINES - OTHER CANCERS
All the month's other
cancer news stories in headline and summary form
To
order - click here!
